Amgen Boosts MariTide Weight-Loss Drug Program, Reports 4% Q1 Sales Growth
AMGN sits 30% above its 52-week low of $261.43.
Summary
Amgen reported a 4% rise in first-quarter product sales, reaching $8.6 billion, with adjusted earnings per share of $5.15, surpassing analyst expectations. More significantly, the company announced a substantial broadening of its development program for the experimental weight-loss drug MariTide, initiating new studies including a trial for patients switching from weekly GLP-1s and advancing Phase 3 trials across various obesity-related conditions. This strategic expansion of the MariTide program is a highly material update, signaling Amgen's increased commitment to a potentially transformative asset in the high-growth weight-loss market. While Q1 financial results were largely covered by earlier news, the detailed pipeline update provides new, forward-looking information. Investors will now closely track MariTide's clinical progress and future regulatory milestones as a key driver for Amgen's long-term growth.
At the time of this announcement, AMGN was trading at $339.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $186.9B. The 52-week trading range was $261.43 to $391.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.